Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Stebbins

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
International Archives of Allergy and Immunology|November 2, 2011
DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virusKarin J Stebbins, Alexander R Broadhead, Alla Musiyenko, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2018
Discovery of potent and selective PPARα/δ dual antagonists and initial biological studiesJason D Jacintho, Christopher S Baccei, Yalda Bravo, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|February 13, 2016
In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their useHans C Helms, N Joan Abbott, Malgorzata Burek, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammationGretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
ACS Chemical Neuroscience|January 24, 2024
Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment EfficacyThomas O Schrader, Kym I Lorrain, Didier Bagnol, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 31, 2024
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosisMichael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
Scientific Reports|May 8, 2024
Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosisMichael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
British Journal of Pharmacology|July 24, 2010
A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelJ S Swaney, C Chapman, L D Correa, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Elife|September 28, 2016
Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recoveryFeng Mei, Klaus Lehmann-Horn, Yun-An A Shen, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
International Archives of Allergy and Immunology|November 2, 2011
DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virusKarin J Stebbins, Alexander R Broadhead, Alla Musiyenko, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2018
Discovery of potent and selective PPARα/δ dual antagonists and initial biological studiesJason D Jacintho, Christopher S Baccei, Yalda Bravo, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|February 13, 2016
In vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their useHans C Helms, N Joan Abbott, Malgorzata Burek, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammationGretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
ACS Chemical Neuroscience|January 24, 2024
Identification and In Vivo Evaluation of Myelination Agent PIPE-3297, a Selective Kappa Opioid Receptor Agonist Devoid of β-Arrestin-2 Recruitment EfficacyThomas O Schrader, Kym I Lorrain, Didier Bagnol, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 31, 2024
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosisMichael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
Scientific Reports|May 8, 2024
Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosisMichael M Poon, Kym I Lorrain, Karin J Stebbins, et al.
British Journal of Pharmacology|July 24, 2010
A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelJ S Swaney, C Chapman, L D Correa, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Elife|September 28, 2016
Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recoveryFeng Mei, Klaus Lehmann-Horn, Yun-An A Shen, et al.
Pageof 6